We are live on ! Find out more

171 hedge funds and large institutions have $3.24B invested in Insmed in 2019 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 83 increasing their positions, 34 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 34

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

38.78% more ownership

Funds ownership: 106.05%144.83% (+39%)

35% more capital invested

Capital invested by funds: $2.39B → $3.24B (+$846M)

8% more funds holding

Funds holding: 158171 (+13)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

36% less call options, than puts

Call options by funds: $9.82M | Put options by funds: $15.3M

Holders
171
Holders Change
+13
Holders Change %
+8.23%
% of All Funds
3.71%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.15%
New
35
Increased
83
Reduced
34
Closed
20
Calls
$9.82M
Puts
$15.3M
Net Calls
-$5.5M
Net Calls Change
-$9.75M
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
76
AQR Capital Management
Connecticut
$2.23M +$160K +5,734 +7%
Wells Fargo
77
Wells Fargo
California
$2.22M +$663K +23,816 +38%
CS
78
Credit Suisse
Switzerland
$2.17M +$615K +22,089 +35%
MOACM
79
Mutual of America Capital Management
New York
$2.14M +$2.27M +81,529 +4,076%
UBS AM
80
UBS AM
Illinois
$1.88M +$742K +26,626 +57%
USAA
81
United Services Automobile Association
Texas
$1.82M -$80.8K -2,899 -4%
JG
82
Jefferies Group
New York
$1.81M -$495K -17,761 -20%
QI
83
QS Investors
New York
$1.72M +$63.3K +2,274 +4%
MSL
84
Mackay Shields LLC
New York
$1.69M +$1.17M +41,836 +172%
UBS Group
85
UBS Group
Switzerland
$1.6M +$1.33M +47,761 +320%
DCM
86
Driehaus Capital Management
Illinois
$1.55M +$1.69M +60,551 New
Barclays
87
Barclays
United Kingdom
$1.47M -$1.81M -64,873 -53%
EAM
88
Erste Asset Management
Austria
$1.46M
DekaBank Deutsche Girozentrale
89
DekaBank Deutsche Girozentrale
Germany
$1.31M +$510K +18,300 +55%
Tudor Investment Corp
90
Tudor Investment Corp
Connecticut
$1.29M +$876K +31,432 +165%
AIG
91
American International Group
New York
$1.26M +$12.8K +461 +0.9%
Manulife (Manufacturers Life Insurance)
92
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.24M -$50K -1,794 -4%
SEI Investments
93
SEI Investments
Pennsylvania
$1.07M +$123K +4,413 +12%
PCM
94
Prelude Capital Management
New York
$1.07M +$708K +25,423 +156%
State Board of Administration of Florida Retirement System
95
State Board of Administration of Florida Retirement System
Florida
$1.05M +$53.2K +1,910 +5%
Legal & General Group
96
Legal & General Group
United Kingdom
$1.03M +$13.9K +500 +1%
UOC
97
UBS O'Connor
Illinois
$1.02M +$1.11M +40,000 New
TI
98
Trexquant Investment
Connecticut
$968K -$243K -8,711 -19%
MIM
99
MetLife Investment Management
New Jersey
$948K +$105K +3,783 +11%
Squarepoint
100
Squarepoint
New York
$883K +$308K +11,046 +47%

INSM Hedge Fund Activity: Q2 2019 in Review

171 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2019, worth a combined $3.24B — up 35% from $2.39B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new INSM positions and 20 closed out — a net gain of 15 holders — while 83 added to existing stakes and 34 trimmed.

The largest buyer was Amundi Asset Management US, adding an estimated $864M. The largest seller was Fidelity Investments, cutting an estimated $29M.

  • 171 institutional investors held Insmed (INSM) as of Q2 2019, up from 158 in Q1 2019.
  • Funds reported $3.24B of Insmed stock for Q2 2019, up 35% quarter-over-quarter.
  • 35 funds opened new Insmed positions in Q2 2019 and 20 closed out, a net change of +15 holders.
  • The largest Insmed buyer in Q2 2019 was Amundi Asset Management US, an estimated $864M added.
  • The largest Insmed seller in Q2 2019 was Fidelity Investments, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2019.